Humana (HUM) Receiving Somewhat Positive Media Coverage, Accern Reports
Media headlines about Humana (NYSE:HUM) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Humana earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the insurance provider an impact score of 45.7635588970227 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Buy the position in Healthcare Stock: Humana Inc. (HUM) – Street Observer (press release) (streetobserver.com)
- Humana Inc. (NYSE:HUM) Stock Traded Above Its 50 Day Moving Average – Modern Readers (modernreaders.com)
- Humana Inc. (HUM) Raised to Buy at ValuEngine (americanbankingnews.com)
- Anthem cuts back Obamacare coverage in Missouri to 68 counties – Business Insider (businessinsider.com)
- Humana Inc. (HUM) Saw a 52-Week High – Modern Readers (modernreaders.com)
Several equities analysts have commented on the stock. ValuEngine upgraded shares of Humana from a “hold” rating to a “buy” rating in a report on Friday. BidaskClub upgraded shares of Humana from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Morgan Stanley upped their price target on shares of Humana from $269.00 to $276.00 and gave the company an “overweight” rating in a research note on Thursday, August 17th. UBS Group AG restated a “neutral” rating and issued a $250.00 price target (up from $237.00) on shares of Humana in a research note on Wednesday, August 9th. Finally, Deutsche Bank AG upped their price target on shares of Humana from $234.00 to $243.00 and gave the company a “hold” rating in a research note on Monday, August 7th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $244.35.
Humana (HUM) opened at 258.75 on Tuesday. The stock has a 50 day moving average of $245.10 and a 200-day moving average of $228.40. The company has a market cap of $37.39 billion, a PE ratio of 21.29 and a beta of 0.87. Humana has a 12-month low of $163.50 and a 12-month high of $259.46.
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.08 by $0.41. Humana had a return on equity of 15.85% and a net margin of 3.37%. The company had revenue of $13.53 billion during the quarter, compared to analyst estimates of $13.61 billion. During the same quarter in the previous year, the firm earned $2.30 earnings per share. On average, equities research analysts anticipate that Humana will post $11.55 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Tuesday, August 29th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.62%. The ex-dividend date of this dividend is Thursday, September 28th. Humana’s payout ratio is 13.06%.
In other news, SVP Brian P. Leclaire sold 4,971 shares of the business’s stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the completion of the transaction, the senior vice president now owns 14,258 shares of the company’s stock, valued at $3,421,920. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce D. Broussard sold 12,000 shares of the business’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $251.88, for a total value of $3,022,560.00. Following the transaction, the chief executive officer now directly owns 80,086 shares of the company’s stock, valued at approximately $20,172,061.68. The disclosure for this sale can be found here. Insiders have sold 42,977 shares of company stock valued at $10,777,906 in the last three months. 0.80% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/05/humana-hum-receiving-somewhat-positive-media-coverage-accern-reports.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.